NCT03082677View on ClinicalTrials.gov

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

September 2, 2021

Study Completion Date

September 2, 2021

Conditions

Myeloid Hematologic MalignancyLymphoid Hematologic Malignancy

Interventions

DRUG

Ixazomib

Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

collaborator

Millennium: The Takeda Oncology Company

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03082677 - Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter